$421.99−1.97 (−0.46%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Madrigal Pharmaceuticals (MDGL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
14 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue history is too short to read a growth trend, net margin −30.1%. Worth your attention in FY25: Share count (+35.7%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲432.1%
958.4
FY21→FY25CAGR —
Net income ($M)▲38.1%
−288.3
FY21→FY25CAGR —
Free cash flow ($M)▲58.4%
−190.0
FY21→FY25CAGR —
Diluted EPS▲41.3%
−12.85
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+35.7%
16.5mn → 22.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$467.0K
−68.1% YoY in FY25 · 0.0% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-30¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Operating Net
Net margin -30.1% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7401, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,427,940.0 | 958,403.0 | 180,133.0 | 0.0 | 0.0 | 0.0 | ▲432.1% | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 387,893.0 | 388,525.0 | 236,718.0 | 272,350.0 | 245,441.0 | 205,164.0 | ▲64.1% | +17.3% |
Selling, general & admin | 1,192,698.0 | 869,975.0 | 441,290.0 | 108,146.0 | 48,130.0 | 37,318.0 | ▲97.1% | +119.7% |
Total operating expenses | 1,580,591.0 | 1,258,500.0 | 678,008.0 | 380,496.0 | 293,571.0 | 242,482.0 | ▲85.6% | +50.9% |
Operating incomefeeds ROC rank | −152,651.0 | −300,097.0 | −497,875.0 | −380,496.0 | −293,571.0 | −242,482.0 | ▲39.7% | — |
Other income, net | −2,812.0 | 11,813.0 | 31,983.0 | 6,866.0 | −1,779.0 | 636.0 | — | — |
Pretax income | −155,463.0 | −288,284.0 | −465,892.0 | −373,630.0 | −295,350.0 | −241,846.0 | ▲38.1% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −155,463.0 | −288,284.0 | −465,892.0 | −373,630.0 | −295,350.0 | −241,846.0 | ▲38.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −8.14 | −12.85 | −21.90 | −19.99 | −17.23 | −14.63 | ▲41.3% | — |
Diluted shares (mn) | 30.31 | 22.43 | 21.27 | 18.69 | 17.14 | 16.54 | ▲5.5% | +7.9% |
| Margins | ||||||||
Gross margin | —A | —A | —A | — | — | — | — | — |
Operating margin | −10.7% | −31.3% | −276.4% | — | — | — | ▲245.1pp | — |
Net margin26th pct in Healthcare | −10.9% | −30.1% | −258.6% | — | — | — | ▲228.6pp | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Madrigal Pharmaceuticals' revenue last fiscal year?
Madrigal Pharmaceuticals reported revenue of $958.4M in fiscal 2025, up 432.1% from fiscal 2024.
What was Madrigal Pharmaceuticals' net income?
Madrigal Pharmaceuticals reported net income of −$288.3M in fiscal 2025, a net margin of −30.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

